M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
8
Registration Number
NCT06284486
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

First Posted Date
2024-02-29
Last Posted Date
2024-11-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
29
Registration Number
NCT06284564
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

First Posted Date
2024-02-29
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
18
Registration Number
NCT06285890
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Early Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-05-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
32
Registration Number
NCT06285825
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-02-16
Last Posted Date
2024-10-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT06263491
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-02-15
Last Posted Date
2024-11-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT06261060
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Understanding Patient Experience Among Asians At MD Anderson

Recruiting
Conditions
First Posted Date
2024-02-14
Last Posted Date
2024-11-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
520
Registration Number
NCT06259253
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

First Posted Date
2024-02-09
Last Posted Date
2024-05-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT06250335
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath